A vaccinia virus-based RNA expression system enabled high-level cytoplasmic expression of RNA aptamers directed against the intracellular domain of the ␤2 integrin LFA-1, a transmembrane protein that mediates cell adhesion to intercellular adhesion molecule-1 (ICAM-1). In two different cell types, cytoplasmic expression of integrinbinding aptamers reduced inducible cell adhesion to ICAM-1. The aptamers specifically target, and thereby define, a functional cytoplasmic subdomain important for the regulation of cell adhesion in leukocytes. Our approach of aptamercontrolled blocking of signaling pathways in vivo could potentially be applied wherever targeted modulation of a signaltransduction cascade is desired.
To understand or control the functions of individual intracellular protein subdomains in vivo, general strategies to create and employ specific modulators of macromolecular interactions are needed. Therefore, a major biological and medical challenge is to identify such selective tools (1) (2) (3) (4) (5) . Here we describe an approach based on cytoplasmic domain recognition of the ␤2 integrin LFA-1 by synthetic ligand-binding RNA aptamers (6) (7) (8) (9) (10) (11) isolated from a combinatorial RNA library, their high-level expression in the cytoplasm of leukocytes, and investigations into their biological effects in vivo.
Integrins are versatile heterodimeric transmembrane proteins that mediate adhesive interactions with extracellular matrix and cell-specific counterreceptors and are implicated in diverse biological processes, including apoptosis, cell-cycle regulation, cell migration, blood clotting, memory, and leukocyte function (12) . The cytoplasmic domains of integrins play important roles in regulating cell adhesion (13, 14) , probably by linking signaling events inside the cell to the extracellular domains, but the precise mechanisms are unclear. The ␤2 integrin LFA-1 (␣L␤2, CD11a͞CD18) mediates adhesion of leukocytes in immune and inflammatory responses by binding to cellular ligands (15) , the intercellular adhesion molecules ICAM-1, -2, or -3. A large body of data implicates the cytoplasmic domain of the ␤2 chain in the regulation of LFA-1-mediated adhesiveness, presumably through its interactions with intracellular proteins and͞or the membraneproximal cytoskeleton (16) , and some candidate cytoplasmic ligands have recently been identified (17) (18) (19) (20) . Further insights into these mechanisms may be gained by specifically inhibiting the LFA-1-mediated inside-out signal transduction in vivo. Our objectives were the selection of aptamers that bind to the cytoplasmic domain of CD18, the development and application of a system allowing high-level expression of aptamers within the cytoplasm of leukocytes, and investigation into their biological effects in the context of the living cell.
MATERIALS AND METHODS
In Vitro Selection of CD18-Binding RNA Aptamers. An RNA library with a complexity of 5 ϫ 10 14 different molecules was synthesised by in vitro T7-transcription from the PCRamplified synthetic DNA pool MF76.1: 5Ј-TCTAATACGAC-TCACTATAGGGCGCTAAGTCCTCGCTCA-N40-ACGC-GCGACTCGGATCCT-3Ј; primer MF39.1: 5Ј-TCTAATA CGACTCACTATAGGGCGCTAA GTCCTCGCTCA-3Ј (italic, T7-promotor; bold, BamHI restriction site); primer Mic20.1: 5Ј-GTAGGATCCGAGTCGCGCGT-3Ј (bold, BamHI restriction site) as described (21) . CNBr-activated Sepharose was derivatized with synthetic peptides (CD18cyt, MF2G) or blocked with Tris⅐HCl (pH 8.0) alone according to the manufacturer's protocol. For the preselection, 50-75 l of either Tris-blocked or MF2G-derivatized Sepharose was incubated with 2-3 nmol ␣-32 P-labeled RNA in 150 l of binding buffer (buffer B: 4.3 mM K 2 HPO 4 , 1.4 mM NaH 2 PO 4 , 150 mM NaCl, 1.0 mM MgCl 2 , 0.1 M CaCl 2 ) for 1 h at 23°C. The slurry was transferred into a plastic column and eluted in small fractions (75 l) with buffer B. For the actual selection, the initial four fractions were precipitated and incubated with 25-50 l of CD18cyt-Sepharose (4.5 mg͞ml gel) in 100 l of buffer B for 1 h at 23°C. Removal of nonbinding RNAs was achieved by washing with 200 Sepharose-volumes of binding buffer (5-10 ml). Bound RNAs were eluted by washing with buffer B adjusted to 6 M guanidinium-HCl. Eluted fractions were quantified by Cherenkov counting, ethanol-precipitated in the presence of 10 -20 g of glycogen, and reversetranscribed as described (22) ; cDNA was PCR-amplified, followed by in vitro transcription. For cycle one, 29 nmol of RNA and 120 l of CD18cyt-Sepharose in a total volume of 475 l were used. After cycle 11, binding sequences were PCR-amplified with primers Mic20.1 and SK40.4 (5Ј-TCTA-ATACGACTCACTATAGGGCTGCAGAGTCCTCGCTCA-3Ј; italic, T7-promotor; bold, PstI restriction site) to introduce a PstI restriction site, cloned, and sequenced as described (22) .
Transfection of Cells with vaccinia T7 (vT7) and vaccinia T7-RNA (vTR). Jurkat E6 and peripheral blood mononuclear cells (PBMC) were isolated according to standard protocols (23) . The sequence of the T7-RNA expression cassette (TR), shown here without inserted aptamer (5Ј-GTTAAC-GCATGCTAATACGACTCACTATAgggagaccacaacggtttcccGGGCG-CAAGTTACTAGT-TGGCCA-AGATCT-TAATTAAtagcataaccccttggggcctctaaacgggtcttgaggggttttttgctGTCGAC-GCGG-CCGC-3Ј; bold, restriction sites in the order in which they appear HpaI, SphI, XbaI, SpeI, BalI, BglII, PacI, SalI, and NotI; italic, T7-promotor; lower case, stabilizing stem-loops) was inserted into the vector pTkg (24, 25) tion sites (TR-aptamer; for an overview see Fig. 2 A) . The construction of the expression cassette with synthetic oligonucleotides by PCR and the insertion of the aptamer-encoding sequences via XbaI and PacI restriction sites will be described elsewhere. Vaccinia expression constructs (vTR-aptamer) were derived via recombination between the TR vector and wild-type vaccinia virus (WR strain), high-titer virus stocks were generated as described (26) , and double infections with recombinant vaccinia viruses and a vaccinia virus coding for T7-RNA polymerase (vT7) were carried out as described previously (20) . Briefly, 2 ϫ 10 6 cells were collected by centrifugation, washed with PBS, resuspended in 300 l of RPMI medium 1640; 100-150 l of each virus stock (multiplicity of infection of Ϸ10 plaque-forming units per cell, sonicated for 10 s) was added and incubated for 2 h at 37°C, followed by addition of 4 ml of RPMI͞10% fetal calf serum and additional incubation for between 1 and 7 h. Dot Blot Analysis of Cytoplasmatic Aptamers. Approximately 4 ϫ 10 6 Jurkat E6 cells were infected with vaccinia viruses expressing aptamer RNA and T7-RNA polymerase. RNA was isolated as described (26) and blotted onto a Hybond N membrane (DuPont͞NEN) according to the manufacturer's protocol. Hybridization of virus-expressed RNA was carried out for 1 h by incubation of cellular RNA in prehybridization buffer (5ϫ SSC, 0.1% SDS, 5ϫ Denhardt's reagent, 5% dextran sulfate, 100 g͞ml tRNA) at 55°C, followed by incubation in the presence of 20 pmol of radiolabeled probe MicTR1͞ 28.1 (5Ј-CAAAAAACCCCTCAAG ACCCGTTTAGAG-3Ј) in a total volume 4.0 ml for 1 h. Dot-blots were then washed with Ϸ20 ml of 2ϫ SSC͞0.1% SDS (2ϫ)͞1ϫ SSC͞0.1% SDS (2ϫ) and 0.5ϫ SSC͞0.1% SDS (2ϫ) at 55°C for 30 min and quantified by PhosphorImaging.
Gel Shift Assays. Jurkat E6 cells (4 ϫ 10 7 ) were lysed in 400 l of lysis buffer (PBS, 0.5% Triton X-100, 0.5 g͞ml aprotinin, 0.5 g͞ml leupeptin, 1 mM PMSF, and 1 mM MgCl 2 ) and incubated at 0°C for 20 min. Nuclei were removed by centrifugation at 3,000 ϫ g for 10 min, and the supernatant was clarified by centrifugation at 10,000 ϫ g for 10 min. To 3 l of this lysate, 2 g of purified mAb (MHM23, OKT3) or 2 l of ascites fluid (MEM170) were added and adjusted to 1ϫ PBS in a total volume of 7 l. After incubation at 0°C for 2-3 h, 5 l of PBS containing 3 mM DTT, 1 mM MgCl 2 , 30 units of RNasin, 75-120 M tRNA, 20% glycerol, and 7.5 g of BSA were added, and the mixture was incubated at 0°C for 15 min. Following incubation, 30 -60 fmol of 5Ј-32 P-labeled TRaptamer in 3 l of PBS and 1 mM MgCl 2 , heated to 95°C for 30s and cooled to 23°C for 10 min, was added, and the mixture was incubated at 23°C for 30 min. The lysate͞aptamer͞ antibody mixture was loaded onto a native 4.5% polyacrylamide gel (acrylamide͞bisacrylamide, 60:1) containing 2% glycerol and electrophoresed at 150 V for 2.5 h in 0.25ϫ TAE electrophoresis buffer. Gel shifts employing synthetic biotinylated peptides were performed as follows: 5 l of 3 nM radiolabeled aptamer RNA in PBS (pH 7.4) was heated to 95°C for 30 s and renatured for 10 min at 23°C. Biotinylated peptide was incubated with 2 mg͞ml streptavidin in 20 mM Tris⅐HCl (pH 7.4) in a total volume of 6 l. To this solution, a pre-mix was added to adjust the concentrations in the final 20 l reaction volume to 1ϫ PBS, 1 mM DTT, 1 mM MgCl 2 , 7.5% glycerol, 2.5 mg͞ml BSA, 40 M tRNA, and 2 units͞l RNasin, and the mixture was preincubated for 20 min at 23°C. The aptamer solution (5 l) was added, incubated for 20 min at 23°C, and electrophoresed on a native 6% polyacrylamide gel as described above.
Adhesion Assays. The ICAM-1-Rg fusion protein was expressed in COS-7 cells, purified from culture supernatants by protein A-Sepharose, eluted, resuspended in PBS, and coated onto plastic dishes as described (20) . Jurkat cells or PBMC (2 ϫ 10 6 ) were infected with recombinant vaccinia viruses and incubated for 4-8 h at 37°C. After centrifugation, cells were resuspended in RPMI medium 1640 and incubated for 5 min at 37°C with or without the addition of 40 ng͞ml phorbol 12-myristate 13-acetate (PMA). Cells were subsequently allowed to adhere to ICAM-1-Rg coated dishes at 37°C for 30 min and the bound fraction was determined with the aid of an ocular reticle.
RESULTS AND DISCUSSION
The RNA library was subjected to 11 cycles of in vitro selection by binding to a 46-mer peptide corresponding to the complete cytoplasmic domain of CD18 (CD18cyt) immobilized on a Sepharose matrix (Fig. 1A) . From the enriched pool, 80 aptamers were cloned and sequenced. Based on sequence motifs, these aptamers can be subdivided into either four classes or orphan sequences without any obvious relationship to each other. In vitro binding to the CD18cyt-peptide was confirmed for several clones (Fig. 1B) by using column-binding assays (data not shown). The binding affinity of monoclonal aptamers to the immobilized CD18cyt-peptide was between 500 and 1,000 nM. No binding of individual aptamers to underivatized Sepharose was observed.
Four sequences were chosen for the cytoplasmic expression studies. Three of them, D20, D28, and D31, are CD18-binders, and the fourth sequence, D42, is a nonbinding negative control sequence of the same length and with primer-binding sites identical to the specific aptamers (Fig. 1B) . First, a TR vector was constructed where the T7 promoter is located upstream of aptamer-coding DNA inserted between 5Ј and 3Ј stem-loop structures that serve as RNA-stabilizing motifs and are required for correct termination of the T7 transcripts (27) (Fig.  2A) . The resulting transcripts are called TR-aptamers. As negative controls, we also used a TR vector lacking the aptamer sequence and one that expressed the nonbinding negative control sequence TR-D42. Importantly, TRaptamers were confirmed to exhibit the same in vitro binding behavior to the CD18cyt-peptide when expressed in the context of the flanking stem-loop structures (data not shown).
Cytoplasmic RNA expression relies on coinfection of cells with two recombinant vaccinia viruses (27) . One virus, vT7, Proc. Natl. Acad. Sci. USA 96 (1999) codes for the bacteriophage T7 RNA polymerase; the other, vTR-aptamer, encodes the sequence of the TR-aptamer and is derived from homologous recombination between vaccinia virus and the TR-aptamer vector. The course of RNA expression after coinfection of a Jurkat E6 cell line with vT7 and vTR-D31 is shown in Fig. 2C . Maximal amounts of RNA are reached 7 h postinfection as quantified by dot-blot analysis by using a DNA hybridization probe complementary to the 3Ј terminus of the aptamer expression cassette. Analysis of all TR transcripts in vivo at this peak revealed comparable aptamer RNA levels of roughly 10 6 copies per cell, but only in the presence of vT7 (Fig. 2D) .
Before investigating the biological effects of aptamer expression, we had to confirm that the aptamers are also able to specifically bind endogenous LFA-1. This was demonstrated by incubating radiolabeled aptamers transcribed in vitro from TR-aptamer vectors with crude cytoplasmic lysate from Jurkat E6 cells and subsequent gel electrophoresis under native conditions. As shown in Fig. 3 in two representative experiments, this resulted in a pattern of shifted bands that were aptamer-specific. Aptamer TR-D20 shows a band pattern with significantly reduced electrophoretic mobility (Fig. 3A , lanes 2 and 4) in comparison with the negative controls of lysate-free RNA (lane 1) and nonbinding TR-D42 (lanes 3 and 5) in the presence of a 10 4 -fold excess of tRNA as a nonspecific competitor. To test whether the shifts were also LFA-1-specific, we performed a supershift analysis with two independent LFA-1-specific antibodies (MHM23 and MEM170) directed against the extracellular domain of the ␤-and ␣-subunits of LFA-1, respectively, and the antibody OKT3, which recognizes the -chain of the T cell antigen receptor as a negative control. Addition of either MHM23 or MEM170 (Fig.   FIG. 2 . RNA aptamer expression system based on double infection with recombinant vaccinia viruses. (A) Design of the T7-RNA expression cassette. (B) Schematic representation of the vaccinia virusbased cytoplasmatic RNA aptamer expression system. (C) Course of the expression of TR-encoded aptamer in vT7-coinfected Jurkat E6 cells shown by a representative dot-blot analysis for aptamer TR-D31 (Right). Maximum levels of aptamer expression are seen 7 h postinfection. Quantification (Left) was done as follows: total cellular RNA was isolated, transferred to the blotting membrane and hybridized with 5Ј-32 P-labeled oligonucleotide complementary to the 3Ј-stabilizing stem-loop structure present in all TR constructs. For comparison and quantification, in vitro-transcribed aptamer TR-D20 was treated in the same way. D, Dot blot analysis and quantification of maximally expressed aptamer RNA. Each dot was quantified on a PhosphorImager. Quantification was done as described for C. 3A, lanes 6 and 7) resulted in a supershifted band. In Fig. 3B again both LFA-1-specific antibodies MHM23 and MEM170 (lanes 3 and 5) show the supershifted bands, whereas no supershift was obtained with the noncognate antibody OKT3 (lane 6). The experiments shown in lanes 4 and 7 establish that the aptamer TR-D20 has no direct affinity to either the specific antibody MHM23 or the nonspecific antibody OKT3. When the gel-shift experiment shown in lane 2 was repeated in the presence of 2 M unlabeled TR-D20 aptamer as a specific competitor, all radiolabeled TR-D20 RNA migrated at the level of unbound RNA (data not shown). Analogous results were obtained with TR-D28 and TR-D31, showing that the aptamers recognize endogenous CD18 in crude cell lysates with remarkable specificity.
To test whether the cytoplasmic expression of CD18-specific aptamers has an effect on the biological activity of this integrin, we performed adhesion assays with Jurkat E6 cells or with PBMC (23) . The cells were infected with vaccinia viruses encoding CD18-specific aptamers or various control sequences, and binding of these cells to an important ligand of LFA-1, the ICAM-1 molecule, was assessed in vitro. This system has a further level of control, because we knew that aptamer expression absolutely depends on coinfection of cells with a virus expressing T7 polymerase (Fig. 2D ). Fig. 4A shows that infected Jurkat E6 cells displayed considerable background adhesion to ICAM-1, but this was nonetheless superinducible by PMA, a well known promoter of LFA-1-mediated leukocyte adhesion (15) . Notably, whereas the TR without insert and single infections with wild-type vaccinia virus, vT7, or vTR-D20 had almost no effect, expression of the TR-D20 aptamer in Jurkat cells resulted in an almost complete block of inducible adhesion.
The reproducibility and extension of the method to other systems was tested by performing similar studies with human PBMC, which although normally difficult to transfect, proved   FIG. 4 . Inhibition of PMA-stimulated cell adhesion as a function of aptamer expression. (A) The CD18cyt binder TR-D20 reduces phorbol ester-activated Jurkat cell adhesion to ICAM-1. Jurkat E6 cells infected with recombinant vaccinia viruses were allowed to adhere to plastic dishes coated with a recombinant ICAM-1 chimera as described in Material and Methods. Jurkat E6 cell adhesion to ICAM-1 was superinducible by PMA in the presence of several control viruses (vT7͞vTR, wild-type vaccinia virus, vT7, and vTR-D20). However, induction of CD18cyt-specific aptamer expression (vT7͞vTR-D20, Right) reduced PMA-stimulated Jurkat E6 cell adhesion but not basal adhesion. These results were independently reproduced at least three times. Percentage reflects values normalized to stimulated vT7͞vTR double infection, which was set to 100%. (B) Human PBMC are good targets for protein overexpression by recombinant vaccinia viruses. Cytoplasmic Ig (cIg) fusions of cytohesin-1 subdomains were detected with the help of an FITC-conjugated antihuman Ig antibody preparation in permeabilized PBMC. Upper Left, control infection, no recombinant molecules expressed; Upper Right, cIg-domains alone; Lower Left, cIg-PH; Lower Right, cIg-PHϩc-domain. (C) TR-D20 specifically reduces PMA-stimulated adhesion of PBMC to ICAM-1. Aptamers or control proteins were expressed in PBMC by recombinant vaccinia viruses as described above. PMA-stimulated adhesion of these cells to ICAM-1 was equivalent when the TR-D42 aptamer, cIg, or cIg-PH control proteins were expressed, but stimulated cell adhesion was dramatically reduced after expression of the intact PH ϩ c-domain of cytohesin-1 (cIg-PHϩc) or of the TR-D20 aptamer. (Fig. 4B ). These controls, chosen because the cytoplasmic cytohesin-1, has previously been shown to be an important regulator of ␤2 integrin adhesive function (20, 28, 29) , and the aptamer viruses were tested in adhesion assays with these cells as described above. The cytohesin-1 PHϩc-domains (cIgPHϩc) had a strongly suppressive effect on PMA-inducible adhesion, whereas neither the isolated PH domain (cIg-PH), which shows considerably reduced phospholipid binding and membrane association (29) nor the control protein had any effect (Fig. 4C) . These results are in accordance with published data obtained with Jurkat cells (28) . Most importantly, Fig. 4C also shows that TR-D20 aptamer mediated reduction of PMAinducible adhesion in PBMC is similar to that observed with cIg-PHϩc, whereas the negative control sequence TR-D42 had no effect on ␤2 integrin-mediated adhesion to ICAM-1. Taken together, these results indicate that the adhesive function of LFA-1 was specifically reduced in Jurkat E6 cells and PBMC by the cytoplasmic expression of an aptamer selected in vitro to bind the cytoplasmic portion of the receptor (Fig. 4 A and C) (15) .
To define the binding site of the aptamers on the CD18cyt, gel-shift experiments were performed with three synthetic CD18cyt peptide fragments (Fig. 5) . No binding to the Cterminal half of CD18cyt (peptide A23) was observed with any of the aptamers, but TR-D20, TR-D28, and, more weakly, TR-D31 all bound to both the N-terminal peptide B16 and the middle portion C17. B16 and C17 overlap by eight amino acids, including a cluster of three basic arginine residues. That this highly positively charged cluster was selected by the aptamers as a binding site on CD18cyt is not surprising, because an aptamer is a highly negatively charged molecule. As expected, the negative-control aptamer TR-D42 exhibited no binding to any of the three fragments used, confirming that the peptidefragment recognition is aptamer-specific.
How do our data fit into the current picture of intracellular processes involved in integrin activation? Numerous studies have tried to address the mechanisms involved by mutational analyses of integrin intracellular domains and subsequent functional tests. A related focus of interest has been the biochemical and genetic isolation of cellular factors that bind to integrin receptors from the cytoplasmic side. A variety of proteins have emerged whose interaction sites with the ␤2 cytoplasmic tail may be targeted by some of the aptamers presented here [e.g., cytohesin-1 (20) , ␣-actinin (18), and filamin (19) ]. Indeed, there is some overlap of the aptamerbinding region with the minimal ␣-actinin-binding sequence in the ␤2 cytoplasmic tail, but the correlation is not perfect. Future studies will have to investigate whether the aptamers target intracellular processes due to known interactions-if so, our approach will provide an elegant means of testing the relevance of some of these-or whether novel interactions are involved in the observed phenomena.
Most of our current knowledge regarding factors and mechanisms that control integrin activation stems from mutational analyses of integrin domains. This study shows that it is now feasible to address this issue by retaining the genetic integrity of the wild-type CD18 cytoplasmic domain. We established that the intracellular expression of CD18cyt-specific aptamers can affect the functional state of endogenous LFA-1 molecules. Futhermore, we provide evidence that these ''intramers'' target a specific subdomain of the ␤2 cytoplasmic tail, implicating this region as important for the proper function of the endogenous LFA-1 receptor with respect to its adhesion to ICAM-1. Above all, we have shown that it is possible to express high levels of functional in vitro-selected RNA aptamers in the cytoplasm of eukaryotic cells. Our data demonstrate that cytoplasmic aptamers are capable of targeting receptors that are anchored in the plasma membrane compartment, thus opening an even wider application potential for aptamer technology compared with what are already a number of significant studies on nuclear aptamer expression (30) (31) (32) or translational regulation (33) .
